LSD1/HDAC-IN-1, also known by its CAS number 3056145-98-0, is a small molecule inhibitor that targets lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs). This compound is primarily studied for its potential therapeutic applications in cancer and neurodegenerative diseases, as it plays a crucial role in regulating gene expression through epigenetic modifications. LSD1 is involved in the demethylation of histone proteins, which affects chromatin structure and gene accessibility, while HDACs are responsible for the removal of acetyl groups from histones, leading to a more compact chromatin state and transcriptional repression. The inhibition of these enzymes can result in the reactivation of silenced genes, promoting differentiation and apoptosis in cancer cells. LSD1/HDAC-IN-1 is characterized by its ability to modulate epigenetic landscapes, making it a valuable tool in research and a potential candidate for drug development in various therapeutic areas. Its specificity and efficacy are subjects of ongoing investigation to better understand its mechanisms and optimize its use in clinical settings.

LSD1/HDAC-IN-1

3056145-98-0: LSD1/HDAC-IN-1, also known by its CAS number 3056145-98-0, is a small molecule inhibitor that targets lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs). This compound is primarily studied for its potential therapeutic applications in cancer and neurodegenerative diseases, as it plays a crucial role in regulating gene expression through epigenetic modifications. LSD1 is involved in the demethylation of histone proteins, which affects chromatin structure and gene accessibility, while HDACs are responsible for the removal of acetyl groups from histones, leading to a more compact chromatin state and transcriptional repression. The inhibition of these enzymes can result in the reactivation of silenced genes, promoting differentiation and apoptosis in cancer cells. LSD1/HDAC-IN-1 is characterized by its ability to modulate epigenetic landscapes, making it a valuable tool in research and a potential candidate for drug development in various therapeutic areas. Its specificity and efficacy are subjects of ongoing investigation to better understand its mechanisms and optimize its use in clinical settings.

LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.

CAS 3056145-98-0

LSD1/HDAC-IN-1

LSD1/HDAC-IN-1

Ref: TM-T201120